Cooper Companies (NASDAQ:COO) Cut to Hold at Wall Street Zen

Wall Street Zen cut shares of Cooper Companies (NASDAQ:COO) from a buy rating to a hold rating in a report published on Saturday,Wall Street Zen reports.

Several other brokerages have also commented on COO. KeyCorp restated a “sector weight” rating on shares of Cooper Companies in a report on Friday, June 5th. Weiss Ratings reiterated a “sell (d)” rating on shares of Cooper Companies in a research report on Friday, September 4th. The Goldman Sachs Group set a $61.00 price target on shares of Cooper Companies in a research note on Wednesday, May 27th. Bank of America restated a “neutral” rating and issued a $65.00 price objective (down from $80.00) on shares of Cooper Companies in a report on Thursday, September 10th. Finally, William Blair cut Cooper Companies from an “outperform” rating to a “market perform” rating in a research report on Thursday, September 10th. Five investment analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $71.47.

Cooper Companies Price Performance

Shares of COO stock opened at $54.22 on Friday. The company has a debt-to-equity ratio of 0.23, a quick ratio of 0.73 and a current ratio of 1.22. Cooper Companies has a fifty-two week low of $51.01 and a fifty-two week high of $89.83. The firm has a market cap of $10.31 billion, a P/E ratio of 18.51, a P/E/G ratio of 2.19 and a beta of 0.82. The business’s 50 day moving average price is $71.25 and its 200-day moving average price is $69.40.

Cooper Companies (NASDAQ:COO) last announced its earnings results on Wednesday, September 9th. The medical device company reported $1.15 EPS for the quarter, beating analysts’ consensus estimates of $1.12 by $0.03. Cooper Companies had a return on equity of 10.90% and a net margin of 13.46%.The company had revenue of $1.07 billion during the quarter, compared to the consensus estimate of $1.10 billion. During the same quarter in the prior year, the company earned $0.49 earnings per share. The firm’s revenue for the quarter was up .5% on a year-over-year basis. Cooper Companies has set its Q4 2026 guidance at 1.050-1.090 EPS and its FY 2026 guidance at 4.510-4.550 EPS. On average, equities research analysts anticipate that Cooper Companies will post 4.53 earnings per share for the current year.

Cooper Companies declared that its Board of Directors has initiated a stock buyback program on Wednesday, September 9th that allows the company to repurchase $3.00 billion in shares. This repurchase authorization allows the medical device company to repurchase up to 22.7% of its stock through open market purchases. Stock repurchase programs are often an indication that the company’s board of directors believes its shares are undervalued.

Institutional Investors Weigh In On Cooper Companies

Several hedge funds have recently bought and sold shares of the business. Avalon Trust Co bought a new stake in shares of Cooper Companies in the 2nd quarter worth approximately $25,000. Root Financial Partners LLC increased its position in Cooper Companies by 104.5% during the 4th quarter. Root Financial Partners LLC now owns 317 shares of the medical device company’s stock valued at $26,000 after buying an additional 162 shares in the last quarter. SJS Investment Consulting Inc. increased its position in Cooper Companies by 107.5% during the 1st quarter. SJS Investment Consulting Inc. now owns 361 shares of the medical device company’s stock valued at $26,000 after buying an additional 187 shares in the last quarter. Elevation Wealth Partners LLC raised its stake in Cooper Companies by 1,136.4% during the second quarter. Elevation Wealth Partners LLC now owns 408 shares of the medical device company’s stock valued at $29,000 after buying an additional 375 shares during the last quarter. Finally, Continuum Advisory LLC purchased a new position in Cooper Companies during the second quarter valued at $30,000. Institutional investors own 24.39% of the company’s stock.

Cooper Companies News Roundup

Here are the key news stories impacting Cooper Companies this week:

• Negative Sentiment: Lower 2026 outlook signals weaker demand. Cooper cut its fiscal 2026 adjusted earnings guidance to $4.51–$4.55 per share from $4.58–$4.66 and reduced revenue guidance to $4.23–$4.25 billion from $4.29–$4.32 billion. The reductions reflect slower-than-expected contact-lens demand, particularly at CooperVision, creating near-term pressure on revenue and profit expectations. The Cooper Companies Faces Near-Term Pressure from Slowing Contact Lens Demand
• Negative Sentiment: U.S. channel inventory reductions raised concerns about underlying demand. Reports highlighted third-quarter results that revealed destocking across the U.S. distribution channel, along with other unfavorable developments. Investors may view the inventory reductions as a sign that customers and distributors are becoming more cautious, potentially delaying a recovery in sales growth. The Cooper Companies Scrutinized Over U.S. Channel Inventory Reductions
• Negative Sentiment: Shareholder investigation adds legal and reputational risk. Rosen Law Firm announced an investigation into whether Cooper issued materially misleading business information. The announcement does not establish wrongdoing, but it adds uncertainty and could increase potential costs or investor concern. Rosen Law Firm Investigation
• Negative Sentiment: Analyst stance became less favorable. Robert W. Baird downgraded Cooper Companies to Neutral, reinforcing caution after the guidance reductions and demand concerns. Cooper Companies Cut to Neutral at Robert W. Baird

Cooper Companies Company Profile

Cooper Companies, Inc is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company develops, manufactures and markets products through two primary business segments: CooperVision and CooperSurgical.

CooperVision specializes in contact lenses, including daily disposable, toric, multifocal, multifocal toric, specialty and myopia-management lenses. Its products are designed to address a range of vision-correction needs, including astigmatism, presbyopia and irregular corneas.